Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Alere has received FDA approval to market its Alere Determine HIV-1/2 Ag/Ab Combo in the United States. The Alere Determine HIV-1/2 Ag/Ab Combo is a rapid point-of-care test that detects both HIV-1/2 antibodies and the HIV-1 p24 antigen, which can appear days after infection and prior to HIV-1/2 antibodies.
BD Diagnostics and Diagenode announced the European-only launch of the Diagenode Bordetella pertussis/parapertussis real-time PCR kit for use on the BD Max system. The kit has been CE-marked and validated to run on the BD Max system using the BD Max ExK DNA-1 extraction kit, an open-system reagent. BD Diagnostics, 800-675-0938 Diagenode, 862-209-4680
PolyScience’s performance programmable circulating baths make it simple to create and run multi-step ramp and soak temperature programs as well as frequently used single temperature testing protocols. The baths have an icon-driven touchscreen display that makes it easy to select and set operational parameters. A built-in electronic keypad speeds and simplifies the entry of text and numerical values. Available in refrigerating/heating and heat-only models, PolyScience performance programmable circulating baths control bath temperatures from −40°C to 200°C with ±0.005°C stability and
Qiagen announced a partnership with Exosome Diagnostics to develop and commercialize high-performance biofluid sample preparation kits for the processing of nucleic acids from exosomes. Combining Exosome Diagnostics’ platform technology approach with select Qiagen consumables and automation platforms has the potential to allow researchers, drug developers, and medical professionals to take repeated, real-time genetic “snapshots” of disease from patients’ blood, urine, or cerebrospinal fluid without the need for tissue biopsy. Qiagen’s exosome technology-driven kits will offer the ability to work with
Immunetics has received FDA clearance for its BacTx rapid test for bacteria in apheresis platelets. The BacTx system is a colorimetric assay that can detect aerobic, anaerobic, gram-negative, and gram-positive bacteria in a single test. The BacTx assay uses a patented, specific, universal bacterial detection reagent that has been shown to detect wild and cultured bacterial strains. BacTx is intended for use as a point-of-issue test performed at the transfusion site on the day of issue. The BacTx assay can
ELGA Process Water introduces the Medica Pro electrodeionization (EDI) water purification system. The system consistently produces high-purity water at economical running costs for immunochemistry and general chemistry automated clinical analyzers. ELGA’s Pulse technology combined with extended intervals between sanitization reduces maintenance time.
Diagnostic BioSystems’ anti-PIN5 cocktail helps distinguish prostate cancer from benign conditions that mimick cancer. The cocktail works through the combined detection of p504S, p40, and high molecular-weight cytokeratin markers. The markers are particularly relevant in helping to diagnose prostatic intraepithelial neoplasia. The markers also offer utility in difficult cases where tissue may be limited.
Sysmex America has renewed its agreement to distribute Medica’s EasyCell assistant for digital cell image analysis in hematology laboratories. EasyCell uses optical pattern recognition software to automatically locate white cells on a blood smear. It digitally stores, preclassifies, and presents images for review, grouped by cell type, on an LCD display.
Randox Laboratories has received FDA approval for its Acusera immunoassay specialty 1 control for use in U.S. laboratories. The multi-analyte, lyophilized control contains I-25-(OH)2-vitamin D, 25-OH-vitamin D, C peptide, insulin, insulin-like growth factor-1, procalcitonin, parathyroid hormone, anti-thyroglobulin, and anti-thyroperoxidase.
SciGene’s CytoZyme stabilized pepsin is an advanced formulation of pepsin for pretreating tissue samples in nucleic acid probe-based cytogenetic assays, including FISH.
